Hypoglycemic prodrugs of 4-(2,2-dimethyl-1-oxopropyl)benzoic acid

被引:10
作者
Aicher, TD
Bebernitz, GR
Bell, PA
Brand, LJ
Dain, JG
Deems, R
Fillers, WS
Foley, JE
Knorr, DC
Nadelson, J
Otero, DA
Simpson, R
Strohschein, RJ
Young, DA
机构
[1] Novartis Inst Biomed Res, Dept Chem, Summit, NJ 07901 USA
[2] Novartis Inst Biomed Res, Dept Mol & Cellular Biol, Summit, NJ 07901 USA
[3] Novartis Inst Biomed Res, Dept Diabet Pharmacol, Summit, NJ 07901 USA
关键词
D O I
10.1021/jm980438y
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
SAH 51-641 (1) is a potent hypoglycemic agent, which acts by inhibiting hepatic gluconeogenesis. It is a prodrug of 4-(2,2-dimethyl-1-oxopropyl)benzoic acid (2) and 4-(2,2-dimethyl-1-hydroxy propyl)benzoic acid (3), which sequester coenzyme A (CoA) in the mitochondria, and inhibits medium-chain acyltransferase. 1-3 and 4-tert-butylbenzoic acid all cause testicular degeneration in rats at pharmacologically active doses. 14b (FOX 988) is a prodrug of 3, which is metabolized in the liver at a rate sufficient enough to have hypoglycemic potency (an ED50 of 65 mu mol/kg, 28 mg/kg/day, for glucose lowering), yet by avoiding significant escape of the metabolite 3 to the systemic circulation, it avoids the testicular toxicity at doses up to 1500 mu mol/kg/day. 14b was selected for clinical studies.
引用
收藏
页码:153 / 163
页数:11
相关论文
共 29 条